Molecular Partners (MOLN) Stock Price, News & Analysis

Company Overview

Molecular Partners AG (NASDAQ: MOLN) is a clinical-stage biotechnology company headquartered in Zürich, Switzerland, that specializes in the discovery and development of DARPin® (Designed Ankyrin Repeat Protein) therapeutics. DARPin molecules are engineered protein scaffolds designed to mimic and improve upon natural antibodies in terms of stability, specificity and manufacturability. The company applies this proprietary platform to develop multi-specific, targeted therapies for oncology, ophthalmology and immuno-oncology indications.

Since its founding in 2004, Molecular Partners has advanced a diversified pipeline of product candidates through preclinical and clinical stages. Lead programs include abicipar pegol, a long-acting anti-VEGF DARPin currently in late-stage development for wet age-related macular degeneration, and MP0250, a bispecific DARPin targeting VEGF and HGF for multiple myeloma and solid tumors. Additional early-stage candidates explore immuno-oncology approaches, such as T-cell engaging DARPin molecules designed to recruit and activate the patient’s own immune system against tumors.

Molecular Partners maintains strategic partnerships with major global biopharmaceutical companies to co-develop and commercialize DARPin-based treatments. Collaborations include an ophthalmology agreement with AbbVie (following its acquisition of Allergan), as well as oncology partnerships with AbbVie and other research organizations. Manufacturing operations are conducted at state-of-the-art facilities in Switzerland, and the company has established a clinical development presence in the United States to support ongoing and future trials.

The company’s leadership team combines seasoned biotechnology entrepreneurs, academic scientists and experienced drug developers. Chief Executive Officer Dr. Michael Hennig guides corporate strategy and operations, while a senior management team oversees research, development and global partnerships. Under this leadership, Molecular Partners remains focused on advancing its DARPin pipeline toward regulatory milestones and delivering innovative therapies to patients worldwide.

Key Stats

• Today's Range: $3.58 to $3.68
• 50-Day Range: $3.56 to $4.28
• 52-Week Range: $3.36 to $12.22
• Volume: 3,313 shs
• Average Volume: 14,585 shs
• Market Capitalization: $147.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Strong Buy

Molecular Partners Stock Analysis - MarketRank™

Molecular Partners scored higher than 56% of companies evaluated by MarketBeat, and ranked 449th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Molecular Partners has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Molecular Partners has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Molecular Partners are expected to decrease in the coming year, from ($1.93) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Molecular Partners is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Molecular Partners is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Molecular Partners has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Partners has recently decreased by 10.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Molecular Partners does not currently pay a dividend.

Dividend Growth

Molecular Partners does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.10% of the float of Molecular Partners has been sold short.

Short Interest Ratio / Days to Cover

Molecular Partners has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Molecular Partners has recently decreased by 10.55%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Molecular Partners has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Molecular Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.93% of the stock of Molecular Partners is held by insiders.

Percentage Held by Institutions

Only 26.55% of the stock of Molecular Partners is held by institutions.

MOLN Stock Analysis - Frequently Asked Questions

How have MOLN shares performed this year?

Molecular Partners' stock was trading at $4.75 at the beginning of 2025. Since then, MOLN stock has decreased by 23.9% and is now trading at $3.6150.

How were Molecular Partners' earnings last quarter?

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.11.

When did Molecular Partners IPO?

Molecular Partners (MOLN) raised $81 million in an initial public offering on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets served as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of Molecular Partners?

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Molecular Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MOLN
• CIK: 1745114
• Web: www.molecularpartners.com
• Phone: 41-44-755-7700
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Molecular Partners: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +231.0%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.39 million
• Net Margins: N/A
• Pretax Margin: -2,681.69%
• Return on Equity: -42.20%
• Return on Assets: -38.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.28
• Quick Ratio: 15.28

Sales & Book Value

• Annual Sales: $5.65 million
• Price / Sales: 25.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.99 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 40,380,000
• Free Float: 37,981,000
• Market Cap: $146.38 million
• Optionable: Not Optionable
• Beta: 1.10